Brokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Target Price at $14.17

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has earned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $14.17.

BCRX has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. JMP Securities upped their price target on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 6th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. Barclays boosted their price objective on shares of BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the company an “equal weight” rating in a research report on Tuesday, August 6th. Finally, StockNews.com raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Large investors have recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in BioCryst Pharmaceuticals by 15.4% during the fourth quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company’s stock valued at $106,405,000 after buying an additional 2,371,401 shares during the period. Avoro Capital Advisors LLC increased its holdings in shares of BioCryst Pharmaceuticals by 13.0% in the 4th quarter. Avoro Capital Advisors LLC now owns 13,050,000 shares of the biotechnology company’s stock valued at $78,170,000 after acquiring an additional 1,500,000 shares during the period. Deerfield Management Company L.P. Series C raised its position in shares of BioCryst Pharmaceuticals by 62.9% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company’s stock worth $50,279,000 after acquiring an additional 3,140,804 shares in the last quarter. Kynam Capital Management LP lifted its stake in shares of BioCryst Pharmaceuticals by 41.9% during the 1st quarter. Kynam Capital Management LP now owns 6,527,491 shares of the biotechnology company’s stock worth $33,160,000 after purchasing an additional 1,927,491 shares during the last quarter. Finally, Braidwell LP boosted its position in BioCryst Pharmaceuticals by 6.6% during the fourth quarter. Braidwell LP now owns 5,718,477 shares of the biotechnology company’s stock valued at $34,254,000 after purchasing an additional 355,497 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Up 0.4 %

BCRX stock opened at $7.58 on Friday. BioCryst Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $8.88. The stock has a market capitalization of $1.56 billion, a price-to-earnings ratio of -7.08 and a beta of 1.88. The firm’s fifty day simple moving average is $7.82 and its two-hundred day simple moving average is $6.41.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.11. The firm had revenue of $109.30 million for the quarter, compared to the consensus estimate of $98.30 million. The business’s revenue for the quarter was up 34.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.24) earnings per share. As a group, equities research analysts expect that BioCryst Pharmaceuticals will post -0.38 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.